140 related articles for article (PubMed ID: 32231746)
1. Overexpression of Epcam and CD133 Correlates with Poor Prognosis in Dual-phenotype Hepatocellular Carcinoma.
Zhang J; Qi YP; Ma N; Lu F; Gong WF; Chen B; Ma L; Zhong JH; Xiang BD; Li LQ
J Cancer; 2020; 11(11):3400-3406. PubMed ID: 32231746
[No Abstract] [Full Text] [Related]
2. Hepatocellular carcinoma expressing cholangiocyte phenotype is a novel subtype with highly aggressive behavior.
Lu XY; Xi T; Lau WY; Dong H; Zhu Z; Shen F; Wu MC; Cong WM
Ann Surg Oncol; 2011 Aug; 18(8):2210-7. PubMed ID: 21308485
[TBL] [Abstract][Full Text] [Related]
3. Dual-phenotype hepatocellular carcinoma: correlation of MRI features with other primary hepatocellular carcinoma and differential diagnosis.
Zhang L; Chen J; Lai X; Zhang X; Xu J
Front Oncol; 2023; 13():1253873. PubMed ID: 38273849
[TBL] [Abstract][Full Text] [Related]
4. Integrated Genomic and Transcriptomic Analysis reveals key genes for predicting dual-phenotype Hepatocellular Carcinoma Prognosis.
Wang Y; Wang X; Huang X; Zhang J; Hu J; Qi Y; Xiang B; Wang Q
J Cancer; 2021; 12(10):2993-3010. PubMed ID: 33854600
[TBL] [Abstract][Full Text] [Related]
5. Radiomics for diagnosis of dual-phenotype hepatocellular carcinoma using Gd-EOB-DTPA-enhanced MRI and patient prognosis.
Huang X; Long L; Wei J; Li Y; Xia Y; Zuo P; Chai X
J Cancer Res Clin Oncol; 2019 Dec; 145(12):2995-3003. PubMed ID: 31664520
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological Features and Post-resection Prognosis of Double Primary Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
Jung DH; Hwang S; Kim KH; Hong SM; Lee YJ; Ahn CS; Moon DB; Ha TY; Song GW; Park GC; Yu ES; Lee SG
World J Surg; 2017 Mar; 41(3):825-834. PubMed ID: 27812807
[TBL] [Abstract][Full Text] [Related]
7. Genetic alterations and expression of PTEN and its relationship with cancer stem cell markers to investigate pathogenesis and to evaluate prognosis in hepatocellular carcinoma.
Chen D; Li Z; Cheng Q; Wang Y; Qian L; Gao J; Zhu JY
J Clin Pathol; 2019 Sep; 72(9):588-596. PubMed ID: 31126975
[TBL] [Abstract][Full Text] [Related]
8. [Application value of neutrophil lymphocyte ratio combined with age in the diagnosis of dual-phenotype hepatocellular carcinoma].
Wang KD; Lu GY; Diao XP; Wang L; Zhou PC; Ma F; Fan XJ
Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(46):3686-3692. PubMed ID: 36509540
[No Abstract] [Full Text] [Related]
9. Associations of components of PTEN/AKT/mTOR pathway with cancer stem cell markers and prognostic value of these biomarkers in hepatocellular carcinoma.
Su R; Nan H; Guo H; Ruan Z; Jiang L; Song Y; Nan K
Hepatol Res; 2016 Dec; 46(13):1380-1391. PubMed ID: 26932478
[TBL] [Abstract][Full Text] [Related]
10. [The prediction value of enhanced magnetic resonance imaging nomogram model for dual phenotype hepatocellular carcinoma].
Wu Q; Yu YX; Fan YF; Hu S; Yao FR; Wang XM; Hu CH
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(15):1086-1092. PubMed ID: 35436807
[No Abstract] [Full Text] [Related]
11. Immunohistochemical Expression and Clinical Significance of Suggested Stem Cell Markers in Hepatocellular Carcinoma.
Sung JJ; Noh SJ; Bae JS; Park HS; Jang KY; Chung MJ; Moon WS
J Pathol Transl Med; 2016 Jan; 50(1):52-7. PubMed ID: 26581206
[TBL] [Abstract][Full Text] [Related]
12. Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma.
Chan AW; Tong JH; Chan SL; Lai PB; To KF
Histopathology; 2014 Jun; 64(7):935-50. PubMed ID: 24506513
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of putative markers of cancer stem cells in gastric cancer: A retrospective cohort study.
Chen XL; Chen XZ; Wang YG; He D; Lu ZH; Liu K; Zhang WH; Wang W; Li CC; Xue L; Zhao LY; Yang K; Liu JP; Zhou ZG; Hu JK; Mo XM
Oncotarget; 2016 Sep; 7(38):62049-62069. PubMed ID: 27557490
[TBL] [Abstract][Full Text] [Related]
14. Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma.
Kim BH; Park JW; Kim JS; Lee SK; Hong EK
Gut Liver; 2019 May; 13(3):342-348. PubMed ID: 30600675
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of the expression of cancer stem cell-related markers CD133 and CD44 in hepatocellular carcinoma: From patients to patient-derived tumor xenograft models.
Zhao Q; Zhou H; Liu Q; Cao Y; Wang G; Hu A; Ruan L; Wang S; Bo Q; Chen W; Hu C; Xu D; Tao F; Cao J; Ge Y; Yu Z; Li L; Wang H
Oncotarget; 2016 Jul; 7(30):47431-47443. PubMed ID: 27329727
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of the stem cell markers CD133 and ABCG2 expression in esophageal squamous cell carcinoma.
Hang D; Dong HC; Ning T; Dong B; Hou DL; Xu WG
Dis Esophagus; 2012; 25(7):638-44. PubMed ID: 22236447
[TBL] [Abstract][Full Text] [Related]
17. EpCAM as a Predictive Marker of Tumor Recurrence and Survival in Patients Who Underwent Surgical Resection for Hepatocellular Carcinoma.
Noh CK; Wang HJ; Kim CM; Kim J; Yoon SY; Lee GH; Cho HJ; Yang MJ; Kim SS; Hwang JC; Cho SW; Roh J; Kim YB; Kim SJ; Kim BW; Cheong JY
Anticancer Res; 2018 Jul; 38(7):4101-4109. PubMed ID: 29970536
[TBL] [Abstract][Full Text] [Related]
18. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.
Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M
Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019
[TBL] [Abstract][Full Text] [Related]
19. Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantation.
Zen C; Zen Y; Mitry RR; Corbeil D; Karbanová J; O'Grady J; Karani J; Kane P; Heaton N; Portmann BC; Quaglia A
Liver Transpl; 2011 Aug; 17(8):943-54. PubMed ID: 21491582
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor and cancer stem cells in hepatitis C virus-associated liver disease.
Bahnassy AA; Zekri AR; El-Bastawisy A; Fawzy A; Shetta M; Hussein N; Omran D; Ahmed AA; El-Labbody SS
World J Gastroenterol; 2014 Dec; 20(48):18240-8. PubMed ID: 25561791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
